Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non–vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke. We administered 4 NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban in 101 po...
Gespeichert in:
| Veröffentlicht in: | Journal of stroke and cerebrovascular diseases 2018-02, Vol.27 (2), p.338-345 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 345 |
|---|---|
| container_issue | 2 |
| container_start_page | 338 |
| container_title | Journal of stroke and cerebrovascular diseases |
| container_volume | 27 |
| creator | Kanai, Yukie Oguro, Hiroaki Tahara, Nao Matsuda, Hanako Takayoshi, Hiroyuki Mitaki, Shingo Onoda, Keiichi Yamaguchi, Shuhei |
| description | We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non–vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke.
We administered 4 NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban in 101 postcardioembolic strokes with NVAF. In a retrospective study, we measured recurrent stroke volume with magnetic resonance imaging volumetric software and compared them between 10 vitamin K anticoagulant (VKA: warfarin) cases and 13 NOAC cases under anticoagulant therapy.
Of 101 cases, 31 were started with a VKA and switched to NOACs after 10 recurrent strokes. Other 70 cases were directly started with NOACs and 13 cases with NOACs as first anticoagulants had recurrent stroke. The frequency of recurrent stroke during anticoagulant therapy is not different between the VKA group and the 3 NOACs group. Recurrent stroke volume is significantly larger in the VKA group (26.4 cm3) than in the NOACs group (1.2 cm3).
Secondary prevention with NOACs after stroke might be more beneficial than a VKA by reducing recurrent infarct volume. |
| doi_str_mv | 10.1016/j.jstrokecerebrovasdis.2017.09.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1951566563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1052305717304780</els_id><sourcerecordid>1951566563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-d9dc0b02eb1bd16d786b68b811537953c916f0631a424251eb285dc8b2ceadb63</originalsourceid><addsrcrecordid>eNqVUctu1DAUjRCIlsIvIO9ASAl-jJ1kOVQUECOKKJSl5cfNyENiF9sZ1B3_wHfwU3wJTqewYsPKj3N0HjpV9YzghmAinu-aXcoxfAEDEXQMe5WsSw3FpG1w32Dc3qmOCWe07jghd8sdc1ozzNuj6kFKO4wJ4R2_Xx3RHjNGaX9c_Vx7NV4nl1AY0Acwc4zgM7q48UGXYZwnQMpb9D6GrQ8LUUP-BuDRZxUHFZ2_gc_CHNG74H99_3HpsprK91u09lltg3cpo_OoxuXtTFDbeVQ-pydobQuvoFFlFzwaQkQXYIK3Kl4XQ9iXKAtQoh0CPazuDWpM8Oj2PKk-nb38ePq63py_enO63tRmhVe5tr01WGMKmmhLhG07oUWnu1KftT1npidiwIIRtaIryglo2nFrOk0NKKsFO6meHnSvYvg6Q8pycsnAWHJDmJMkPSdcCC5Yob44UE0MKUUY5FV0UykgCZbLbHIn_zWbXGaTuJdltiLy-NZv1hPYvxJ_diqEzYEApfXeQZTJOPAGrItgsrTB_Y_fbwtsvMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951566563</pqid></control><display><type>article</type><title>Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kanai, Yukie ; Oguro, Hiroaki ; Tahara, Nao ; Matsuda, Hanako ; Takayoshi, Hiroyuki ; Mitaki, Shingo ; Onoda, Keiichi ; Yamaguchi, Shuhei</creator><creatorcontrib>Kanai, Yukie ; Oguro, Hiroaki ; Tahara, Nao ; Matsuda, Hanako ; Takayoshi, Hiroyuki ; Mitaki, Shingo ; Onoda, Keiichi ; Yamaguchi, Shuhei</creatorcontrib><description>We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non–vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke.
We administered 4 NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban in 101 postcardioembolic strokes with NVAF. In a retrospective study, we measured recurrent stroke volume with magnetic resonance imaging volumetric software and compared them between 10 vitamin K anticoagulant (VKA: warfarin) cases and 13 NOAC cases under anticoagulant therapy.
Of 101 cases, 31 were started with a VKA and switched to NOACs after 10 recurrent strokes. Other 70 cases were directly started with NOACs and 13 cases with NOACs as first anticoagulants had recurrent stroke. The frequency of recurrent stroke during anticoagulant therapy is not different between the VKA group and the 3 NOACs group. Recurrent stroke volume is significantly larger in the VKA group (26.4 cm3) than in the NOACs group (1.2 cm3).
Secondary prevention with NOACs after stroke might be more beneficial than a VKA by reducing recurrent infarct volume.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2017.09.007</identifier><identifier>PMID: 29033229</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; apixaban ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - epidemiology ; dabigatran ; Dabigatran - administration & dosage ; Dabigatran - adverse effects ; direct thrombin inhibitor ; DOAC ; edoxaban ; factor Xa inhibitor ; Female ; Humans ; Japan - epidemiology ; Magnetic Resonance Imaging ; Male ; NOAC ; Pyrazoles - administration & dosage ; Pyrazoles - adverse effects ; Pyridines - administration & dosage ; Pyridines - adverse effects ; Pyridones - administration & dosage ; Pyridones - adverse effects ; Recurrence ; recurrent ; Retrospective Studies ; Risk Factors ; rivaroxaban ; Rivaroxaban - administration & dosage ; Rivaroxaban - adverse effects ; Secondary Prevention - methods ; Stroke - diagnostic imaging ; Stroke - epidemiology ; Stroke - prevention & control ; Stroke volume ; Thiazoles - administration & dosage ; Thiazoles - adverse effects ; Time Factors ; Treatment Outcome ; warfarin ; Warfarin - administration & dosage ; Warfarin - adverse effects]]></subject><ispartof>Journal of stroke and cerebrovascular diseases, 2018-02, Vol.27 (2), p.338-345</ispartof><rights>2018 National Stroke Association</rights><rights>Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-d9dc0b02eb1bd16d786b68b811537953c916f0631a424251eb285dc8b2ceadb63</citedby><cites>FETCH-LOGICAL-c404t-d9dc0b02eb1bd16d786b68b811537953c916f0631a424251eb285dc8b2ceadb63</cites><orcidid>0000-0002-8024-0930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29033229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanai, Yukie</creatorcontrib><creatorcontrib>Oguro, Hiroaki</creatorcontrib><creatorcontrib>Tahara, Nao</creatorcontrib><creatorcontrib>Matsuda, Hanako</creatorcontrib><creatorcontrib>Takayoshi, Hiroyuki</creatorcontrib><creatorcontrib>Mitaki, Shingo</creatorcontrib><creatorcontrib>Onoda, Keiichi</creatorcontrib><creatorcontrib>Yamaguchi, Shuhei</creatorcontrib><title>Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non–vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke.
We administered 4 NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban in 101 postcardioembolic strokes with NVAF. In a retrospective study, we measured recurrent stroke volume with magnetic resonance imaging volumetric software and compared them between 10 vitamin K anticoagulant (VKA: warfarin) cases and 13 NOAC cases under anticoagulant therapy.
Of 101 cases, 31 were started with a VKA and switched to NOACs after 10 recurrent strokes. Other 70 cases were directly started with NOACs and 13 cases with NOACs as first anticoagulants had recurrent stroke. The frequency of recurrent stroke during anticoagulant therapy is not different between the VKA group and the 3 NOACs group. Recurrent stroke volume is significantly larger in the VKA group (26.4 cm3) than in the NOACs group (1.2 cm3).
Secondary prevention with NOACs after stroke might be more beneficial than a VKA by reducing recurrent infarct volume.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>apixaban</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - epidemiology</subject><subject>dabigatran</subject><subject>Dabigatran - administration & dosage</subject><subject>Dabigatran - adverse effects</subject><subject>direct thrombin inhibitor</subject><subject>DOAC</subject><subject>edoxaban</subject><subject>factor Xa inhibitor</subject><subject>Female</subject><subject>Humans</subject><subject>Japan - epidemiology</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>NOAC</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyridines - administration & dosage</subject><subject>Pyridines - adverse effects</subject><subject>Pyridones - administration & dosage</subject><subject>Pyridones - adverse effects</subject><subject>Recurrence</subject><subject>recurrent</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>rivaroxaban</subject><subject>Rivaroxaban - administration & dosage</subject><subject>Rivaroxaban - adverse effects</subject><subject>Secondary Prevention - methods</subject><subject>Stroke - diagnostic imaging</subject><subject>Stroke - epidemiology</subject><subject>Stroke - prevention & control</subject><subject>Stroke volume</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - adverse effects</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>warfarin</subject><subject>Warfarin - administration & dosage</subject><subject>Warfarin - adverse effects</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUctu1DAUjRCIlsIvIO9ASAl-jJ1kOVQUECOKKJSl5cfNyENiF9sZ1B3_wHfwU3wJTqewYsPKj3N0HjpV9YzghmAinu-aXcoxfAEDEXQMe5WsSw3FpG1w32Dc3qmOCWe07jghd8sdc1ozzNuj6kFKO4wJ4R2_Xx3RHjNGaX9c_Vx7NV4nl1AY0Acwc4zgM7q48UGXYZwnQMpb9D6GrQ8LUUP-BuDRZxUHFZ2_gc_CHNG74H99_3HpsprK91u09lltg3cpo_OoxuXtTFDbeVQ-pydobQuvoFFlFzwaQkQXYIK3Kl4XQ9iXKAtQoh0CPazuDWpM8Oj2PKk-nb38ePq63py_enO63tRmhVe5tr01WGMKmmhLhG07oUWnu1KftT1npidiwIIRtaIryglo2nFrOk0NKKsFO6meHnSvYvg6Q8pycsnAWHJDmJMkPSdcCC5Yob44UE0MKUUY5FV0UykgCZbLbHIn_zWbXGaTuJdltiLy-NZv1hPYvxJ_diqEzYEApfXeQZTJOPAGrItgsrTB_Y_fbwtsvMM</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Kanai, Yukie</creator><creator>Oguro, Hiroaki</creator><creator>Tahara, Nao</creator><creator>Matsuda, Hanako</creator><creator>Takayoshi, Hiroyuki</creator><creator>Mitaki, Shingo</creator><creator>Onoda, Keiichi</creator><creator>Yamaguchi, Shuhei</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8024-0930</orcidid></search><sort><creationdate>201802</creationdate><title>Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke</title><author>Kanai, Yukie ; Oguro, Hiroaki ; Tahara, Nao ; Matsuda, Hanako ; Takayoshi, Hiroyuki ; Mitaki, Shingo ; Onoda, Keiichi ; Yamaguchi, Shuhei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-d9dc0b02eb1bd16d786b68b811537953c916f0631a424251eb285dc8b2ceadb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>apixaban</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - epidemiology</topic><topic>dabigatran</topic><topic>Dabigatran - administration & dosage</topic><topic>Dabigatran - adverse effects</topic><topic>direct thrombin inhibitor</topic><topic>DOAC</topic><topic>edoxaban</topic><topic>factor Xa inhibitor</topic><topic>Female</topic><topic>Humans</topic><topic>Japan - epidemiology</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>NOAC</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyridines - administration & dosage</topic><topic>Pyridines - adverse effects</topic><topic>Pyridones - administration & dosage</topic><topic>Pyridones - adverse effects</topic><topic>Recurrence</topic><topic>recurrent</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>rivaroxaban</topic><topic>Rivaroxaban - administration & dosage</topic><topic>Rivaroxaban - adverse effects</topic><topic>Secondary Prevention - methods</topic><topic>Stroke - diagnostic imaging</topic><topic>Stroke - epidemiology</topic><topic>Stroke - prevention & control</topic><topic>Stroke volume</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - adverse effects</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>warfarin</topic><topic>Warfarin - administration & dosage</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanai, Yukie</creatorcontrib><creatorcontrib>Oguro, Hiroaki</creatorcontrib><creatorcontrib>Tahara, Nao</creatorcontrib><creatorcontrib>Matsuda, Hanako</creatorcontrib><creatorcontrib>Takayoshi, Hiroyuki</creatorcontrib><creatorcontrib>Mitaki, Shingo</creatorcontrib><creatorcontrib>Onoda, Keiichi</creatorcontrib><creatorcontrib>Yamaguchi, Shuhei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanai, Yukie</au><au>Oguro, Hiroaki</au><au>Tahara, Nao</au><au>Matsuda, Hanako</au><au>Takayoshi, Hiroyuki</au><au>Mitaki, Shingo</au><au>Onoda, Keiichi</au><au>Yamaguchi, Shuhei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2018-02</date><risdate>2018</risdate><volume>27</volume><issue>2</issue><spage>338</spage><epage>345</epage><pages>338-345</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non–vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke.
We administered 4 NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban in 101 postcardioembolic strokes with NVAF. In a retrospective study, we measured recurrent stroke volume with magnetic resonance imaging volumetric software and compared them between 10 vitamin K anticoagulant (VKA: warfarin) cases and 13 NOAC cases under anticoagulant therapy.
Of 101 cases, 31 were started with a VKA and switched to NOACs after 10 recurrent strokes. Other 70 cases were directly started with NOACs and 13 cases with NOACs as first anticoagulants had recurrent stroke. The frequency of recurrent stroke during anticoagulant therapy is not different between the VKA group and the 3 NOACs group. Recurrent stroke volume is significantly larger in the VKA group (26.4 cm3) than in the NOACs group (1.2 cm3).
Secondary prevention with NOACs after stroke might be more beneficial than a VKA by reducing recurrent infarct volume.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29033229</pmid><doi>10.1016/j.jstrokecerebrovasdis.2017.09.007</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8024-0930</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1052-3057 |
| ispartof | Journal of stroke and cerebrovascular diseases, 2018-02, Vol.27 (2), p.338-345 |
| issn | 1052-3057 1532-8511 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1951566563 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Oral Aged Aged, 80 and over Anticoagulants - administration & dosage Anticoagulants - adverse effects apixaban Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Atrial Fibrillation - epidemiology dabigatran Dabigatran - administration & dosage Dabigatran - adverse effects direct thrombin inhibitor DOAC edoxaban factor Xa inhibitor Female Humans Japan - epidemiology Magnetic Resonance Imaging Male NOAC Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyridines - administration & dosage Pyridines - adverse effects Pyridones - administration & dosage Pyridones - adverse effects Recurrence recurrent Retrospective Studies Risk Factors rivaroxaban Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Secondary Prevention - methods Stroke - diagnostic imaging Stroke - epidemiology Stroke - prevention & control Stroke volume Thiazoles - administration & dosage Thiazoles - adverse effects Time Factors Treatment Outcome warfarin Warfarin - administration & dosage Warfarin - adverse effects |
| title | Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A13%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20Recurrent%20Stroke%20Volume%20and%20Prognosis%20between%20Warfarin%20and%20Four%20Non%E2%80%93Vitamin%20K%20Antagonist%20Oral%20Anticoagulants'%20Administration%20for%20Secondary%20Prevention%20of%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Kanai,%20Yukie&rft.date=2018-02&rft.volume=27&rft.issue=2&rft.spage=338&rft.epage=345&rft.pages=338-345&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2017.09.007&rft_dat=%3Cproquest_cross%3E1951566563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1951566563&rft_id=info:pmid/29033229&rft_els_id=S1052305717304780&rfr_iscdi=true |